The FDA recently approved Lumoxiti, a CD22-targeting recombinant immunotoxin using Pseudomonas exotoxin A, as a treatment for patients with relapsed or refractory hairy cell leukemia that have received at least two prior systemic therapies [47,51]. The gene discussed is CD22; the disease is hairy cell leukemia.